

ISSUE @ A GLANCE



- Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun**
F. Crea 139

CardioPulse


- The ESC Working Group on e-Cardiology**
P. Dilaveris and J. Lumens 143
- Virtual medical education during the COVID-19 pandemic: how to make it work**
A. Idris and B. Edris 145
- The Danish Society of Cardiology**
S.D. Kristensen and J.T. Sorensen 147
- The Syncope Unit of Tehran Heart Center**
S. Sadeghian, A. Aminorroaya, and M. Tajdini 148
- Weekly Journal Scan**
COVID 19: in the eye of the cytokine storm
G. Liuzzo and C. Patrono 150

STATE OF THE ART REVIEW

- Heart failure and cardiomyopathies**
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
R. Agarwal, P. Kolkhof, G. Bakris, J. Bauersachs, H. Haller, T. Wada, and F. Zannad 152

CLINICAL RESEARCH

- Heart failure and cardiomyopathies**
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences
J.A.J. Verdonchot, M. Merlo, F. Dominguez, P. Wang, M.T.H.M. Henkens, M.E. Adriaens, M.R. Hazebroek, M. Masè, L.E. Escobar, R. Cobas-Paz, K.W.J. Derks, A. van den Wijngaard, I.P.C. Krapels, H.G. Brunner, G. Sinagra, P. Garcia-Pavia, and S.R.B. Heymans 162



Editorial

- Personalized medicine for dilated cardiomyopathy**
P.M. Elliott 175

Heart failure and cardiomyopathies

- Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study**
J. Tübel, W. Hauke, S. Rump, J. Viereck, S. Batkai, J. Poetzsch, L. Rode, H. Weigt, C. Genschel, U. Lorch, C. Theek, A.A. Levin, J. Bauersachs, S.D. Solomon, and T. Thum 178

Editorial

- Antagonism of miRNA in heart failure: first evidence in human**
A.H. Baker and M. Giacca 189


TRANSLATIONAL RESEARCH

Heart failure and cardiomyopathies

CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure

S. Batkai, C. Genschel, J. Viereck, S. Rump, C. Bär, T. Borchert, D. Traxler, M. Riesenhuber, A. Spannauer, D. Lukovic, K. Zlabinger, E. Hasimbegović, J. Winkler, R. Garamvölgyi, S. Neitzel, M. Gyöngyösi, and T. Thum

192



Editorial

CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease

Y. Devaux and L. Badimon

202

CARDIOVASCULAR FLASHLIGHT

Posture dependent dynamic external outflow graft compression in HeartMate 3™ left ventricular assist device

M. Fürholz, F. Gisler, L. Hunziker, A.T. Huber, and C. Gräni

205

Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin

H. Hu, F. Ma, X. Wei, and Y. Fang

206

End-stage heart failure secondary to low-dose hydroxychloroquine treatment

S. Figliozzi, S. Rizzo, M. De Gaspari, and G. Tarantini

207

Pulmonary ventilation-perfusion mismatch demonstrated by dynamic chest radiography in giant cell arteritis

Y. Yamasaki, K. Hosokawa, H. Tsutsui, and K. Ishigami

208

CORRIGENDA

Corrigendum to: How to slice the pie: heart failure subgroups and their clinical meaning

177

Corrigendum to: Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin

191

Open Access Paper

For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org